IP Library Granted Patent US 7,741,057
Granted Patent B2
US 7,741,057 · App. 11/931,442 · Granted Jun 22, 2010

Method for screening for compounds using MHC class II invariant chain polypeptide and macrophage migration inhibitory factor

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,741,057
App. No.
11/931,442
Granted
Jun 22, 2010
Kind
B2
Abstract

Methods and compositions for using the MHC class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor, or which otherwise modulate the interaction of MIF with CD74 or the consequences of such interaction, in treatment of conditions characterized by locally or systemically altered MIF levels, particularly inflammatory conditions and cancer.

Claims (9)

1. A method for screening compounds for an agonist or antagonist of macrophage migration inhibitory factor (MIF) protein comprising:

contacting, in vitro, an MHC class II invariant chain (Ii) polypeptide with said MIF protein in the presence and absence of a candidate compound, and

comparing the binding interaction of the said MIF protein and said Ii polypeptide in the presence of said candidate compound with their binding interaction in the absence of said candidate compound, whereby

a candidate compound that enhances the binding interaction of said MIF protein with said Ii polypeptide is identified as an agonist of MIF protein, and

a candidate compound that inhibits the binding interaction of said MIF protein with said Ii polypeptide is identified as an antagonist of MIF protein;

wherein said Ii polypeptide comprises the amino acid sequence of SEQ ID NO: 2 or a MIF protein-binding fragment thereof.

2. The method of claim 1 , wherein said Ii polypeptide comprises the amino acid sequence of SEQ ID NO: 2.

3. The method of claim 1 , wherein said Ii polypeptide comprises the MIF protein-binding fragment of the amino acid sequence of SEQ ID NO: 2.

4. The method of claim 3 , wherein said MIF protein-binding fragment comprises amino acids 73-232 of SEQ ID NO: 2.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER INTERNATIONAL INC.
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036368/0311 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER HEALTHCARE SA
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036379/0331 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 25, 2011
From: CYTOKINE PHARMASCIENCES, INC.
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE S.A.
Reel/Frame 027114/0747 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 5, 2010
From: BUCALA, RICHARD J
To: CYTOKINE PHARMASCIENCES, INC.
Reel/Frame 024186/0819 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 5, 2010
From: METZ, CHRISTINE N.
To: CYTOKINE PHARMASCIENCES, INC.
Reel/Frame 024187/0010 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 5, 2010
From: LENG, LIN
To: THE PICOWER INSTITUTE FOR MEDICAL RESEARCH
Reel/Frame 024187/0126 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 5, 2010
From: THE PICOWER INSTITUTE FOR MEDICAL RESEARCH
To: CYTOKINE PHARMASCIENCES, INC.
Reel/Frame 024187/0203 →